Welcome to our new website! If this is the first time you are logging in on the new site, you will need to reset your password. Please contact us at raps@raps.org if you need assistance.
Your membership opens the door to free learning resources on demand. Check out the Member Knowledge Center for free webcasts, publications and online courses.
Our new book is a comprehensive look at a vital part of medicines development and regulatory affairs. Grab your copy today!
Hear from leaders around the globe as they share insights about their experiences and lessons learned throughout their certification journey.
| 14 September 2012 | By Louise Zornoza •
Local Brazilian companies will be the beneficiaries of a new technology transfer regulation that is intended to reduce the country's dependence on foreign drug imports and technology.
The regulation, approved by the Board of Brazil's national regulatory agency, Anvisa, on 13 September 2012, establishes procedures for local companies to enter into drug development and technology transfer partnerships with the National Health Service (SUS). The regulation expands strategic and practical mechanisms for increasing access to new technologies in Brazil, and will lead to an estimated 25% reduction in the country's dependence on health sector imports.
According to Anvisa, proposed partnerships must have a, "High relevance for public health and for the development of the [Brazilian] health-industrial complex," and must be approved by Brazil's Ministry of Health. The new regulation has won the support of the Brazilian drug industry association, Farmabrasil.
Read more:
Read all Breaking News from RegLink
Tags: Imports, Transfer Regulation, Exports, Patents, pharmaceutical, brazil, drug